Molecular Partners AG is a clinical-stage biotechnology company that specializes in the development of Designed Ankyrin Repeat Proteins (DARPins), a novel class of small, highly specific protein therapeutics. Since its founding in 2004 as a spin-off from the University of Zurich, the firm has focused on creating multispecific molecules intended to address a range of serious diseases with precision and improved safety profiles.
The company’s pipeline spans multiple therapeutic areas, including oncology, ophthalmology and infectious disease. Its lead ophthalmology candidate, abicipar pegol, is being evaluated for the treatment of neovascular age-related macular degeneration in collaboration with Allergan. In infectious disease, ensovibep has advanced into late-stage clinical trials for the treatment and prevention of COVID-19. In oncology, Molecular Partners is advancing several DARPin-based immuno-oncology programs designed to engage the immune system directly at the tumor site.
Headquartered in Schlieren, Switzerland, Molecular Partners maintains operations in both Europe and the United States to support its global development and regulatory activities. The company has forged partnerships with major pharmaceutical firms to accelerate clinical programs and leverage its protein engineering platform to create differentiated therapeutic candidates.
Leadership at Molecular Partners is led by Chief Executive Officer Dr. Patrick Amstutz, who brings extensive biopharmaceutical experience to the organization. The management team and board include veterans from the biotech and pharmaceutical industries, underscoring the company’s commitment to advancing its pipeline through rigorous science and strategic collaborations.
AI Generated. May Contain Errors.
